Amgen (AMGN) Tepezza Receives Approval In Japan For The Treatment Of Active Thyroid Eye Disease

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. APGE
6. DFTX
7. GOOGL
8. MU
9. IBM
10. HOOD

Go back to Amgen (AMGN) Tepezza Receives Approval In Japan For The Treatment Of Active Thyroid Eye Disease

Truist Securities Reiterates Buy Rating on Amgen (AMGN)

September 25, 2024 5:43 AM EDT

Truist Securities analyst Robyn Karnauskas reiterated a Buy rating and $320.00 price target on Amgen (NASDAQ: AMGN).

The analyst comments "Earlier this evening, Amgen (AMGN, Buy) provided positive Ph3 updates from two key pipeline programs - Uplizna in gMG and rocatinlimab in atopic... More